

# **Serological Diagnosis of EIA**

**Basic research defines the need for improvement**

**Applied studies prove value of model:**

**3 tier strategy**

**A cooperation between researchers at the  
University of Kentucky and the staff of the  
National Reference Centre for Equine Infectious  
Anemia (IZS-Lazio e Toscana) during  
surveillance for EIA: 2007-2010**

# Serologic Testing – Three Tier Lab System


	Result	Report
ELISA first testing	NEG	NEG
	POS	
Test by AGID	POS	POS
	NEG	
Immunoblot	POS	POS
	NEG	NEG

# Serological Diagnosis of EIA

## Antibody Tests for EIA

AGID (Coggins)	p26	Major core
4 ELISA kits (US)	p26	Core
Immunoblot	gp90, gp45, p26	Env + Core

Envelope more immunogenic  
p26 >40% of virion: ~2000/  
gp90-gp45: minor ~30/



# **Immunoblot Testing for EIA**

**Virus grown, purified and SDS-heat treated**

**Separated into individual proteins**

**by relative molecular mass-PAGE**

**Transferred to membranes**

**Suspect serum tested at 1:20 dilution**

**React with at least 2 major proteins?**

**Surface unit, transmembrane, major core**

**gp90**

**gp45**

**p26**

# Immunoblot Testing for EIA

Responses of horses to  
IV inoculation with  
 $10^3$ TCID<sub>50</sub> of EIAV

gp90

gp45


p26

p15

562

W+

564



0 14 22 28 36 43 49

Days after infection  
infection

0 14 22 28 36

W+ Days after

# Test Expected Results 1999

	1	7
AGID	-	+
CELISA	-	+
Vira-CHEK	-	+
SA-ELISA	-	+
Immunoblot-		+

Rate >99% >99%

# **Reservoirs/Risks/Need: 1999**

**Test all equids: only ~30% tested**

**Estimated error rate:**

**False-negative reactors: ~1% of POS**













**Estimated lab errors: ~1%**

**Estimated overall error rate: ~2% of true +**  
**Miniscule compared to untested reservoir**

**What have we learned since then?**

# Challenges in Serologic Diagnosis of EIAV Infections

## 180-210 days after infection – vaccine strain

Animal	Virus <sup>2</sup>	AGID	EISAs Tests		Immunoblot		
			USkits <sup>3</sup>	IT <sup>4</sup>	p26	gp45	gp90
Experimental infections <sup>5</sup>			1/2/3				
C9	Yes	NEG	+ / + / +	1:24			
C15	Yes	NEG	+ / + / -	<1:6			
C16	Yes	NEG	+ / + / -	<1:6			
C22	Yes	NEG	+ / + / -	<1:6			
C23	Yes	NEG	+ / + / +	<1:6			
B62	Yes	NEG	- / + / -	<1:6			
BT210	Yes	NEG	+ / + / +	1:12			
C50	Yes	NEG	- / + / -	<1:6			
H46	Yes	NEG	+ / + / -	<1:6			
H32	Yes	NEG	+ / + / -	1:6			



# **Major issues: 1999**

**Subjective AGID results:**

**Same as in 1974!**

**Personnel turnover?**

**Eyesight fails?**

**Intense light source?**

**Others?**

**What has changed?**


# **AGID Test Parameters Compared How They Impact Accuracy**

	<b>1970's</b>	<b>Today</b>
<b>Antigen source</b>	<b>Virus</b>	<b>Recombinant</b>
<b>Template used</b>	<b>Large</b>	<b>Smaller</b>
<b>(Brazil</b>		<b>Slides – micro)</b>

**Expectations: Higher rate of False-NEG  
AGID reports with rec-antigen kits and  
smaller format.**

# AGID (Coggins) Test Reactions Expected

Positive Reactions



<1

$\geq 10$

7

4

2


1

<1

**Amount of Antibody to p26  
With constant antigen**

**AGID**  
**(Coggins)**


**POS**



# **“Weak Positive” AGID**

## **Accurate Interpretation Required**

**Ref W<sub>+</sub>  
USDA  
(older)**



**Field  
Sample**

**Read at  
48 hours**


**UK W<sub>+</sub>(Flicker)**



# **“Weak Positive” AGID**

## **Accurate Interpretation Required**


**Ref W+ USDA (newer)**




# **“Weak Positive” AGID**

## **Accurate Interpretation Required**

**Ref W+ USDA**




**UK W+Flicker**



# ELISA Test Reactions

Colors compared to Reference Controls


Spec reading makes it more objective





# Serologic Responses to EIAV – Reference

W+

Animal	Virus <sup>2</sup>	AGID	ELISAs Tests		Immunoblot		
			USkits <sup>3</sup>	IT <sup>4</sup>	p26	gp45	gp90
Reference Positive Serums							
Flicker W+	Yes	NEG	+ / + / +	1:8			
USDA W+	???	1	+ / + / +	1:48			

# **Pilot Study for Three Tier Strategy USDA**

<b>First tier</b>	<b>Private labs</b>	<b>ELISA only</b>
<b>Second</b>	<b>Referral labs</b>	<b>E+ AGID</b>
<b>Third</b>	<b>Reference lab</b>	<b>E+A+Blot</b>

**Maybe up to 30% missed by old strategy**  
**Three Tier Strategy adopted by Oklahoma**


# Serologic Testing for EIA

Usual Sample: total agreement in AGID/ELISA

Some: Interpreted AGID NEG / ELISA POS

Some: AGID misinterpreted and blot +

1 - - W+



# **Serologic Testing for EIA**

**Usual Sample: total agreement in AGID/ELISA**

**Some: Interpreted AGID NEG / ELISA POS**

**Rare: ELISA and Blot POS but AGID NEG**

**Because sample result misinterpreted**

**Or because antibody level too low**

**How many?**

# **Three Tier Strategy: Field Testing Italy 2007-2010**

**All testing at one laboratory**

**First tier**

**ELISA**

**Second**

**E+ AGID**

**Third**

**E+A+Blot**

**Is there a need to adopt it more widely?**

# **Serology Italy – 3 Tier Lab Testing**

	<b>Number</b>	<b>%</b>
<b>Samples</b>	<b>96,468</b>	
<b>+ ELISA</b>	<b>331</b>	<b>0.36</b>
<b>+ E &amp; AGID</b>	<b>124</b>	<b>0.13</b>

# **Serology Italy – 3 Tier Lab Testing**

	<b>Number</b>	<b>%</b>
<b>Samples</b>	<b>96,468</b>	
<b>+ ELISA</b>	<b>331</b>	<b>0.36</b>
<b>+ E &amp; AGID</b>	<b>124</b>	<b>0.13</b>
<b>Discrepant Samples</b>	<b>207</b>	<b>0.21</b>

# Serology Italy – 3 Tier Lab Testing

	Number	%
<b>Samples</b>	<b>96,468</b>	
+ ELISA	331	0.36
+ E & AGID	124	0.13
<b>Discrepant Samples</b>	<b>207</b>	<b>0.21</b>
+ Immunoblot	25	12%



# **Serology Italy – 3 Tier Lab Testing**



	<b>Number</b>	<b>%</b>
<b>Samples</b>	<b>96,468</b>	
<b>+ ELISA</b>	<b>331</b>	<b>0.36</b>
<b>+ E &amp; AGID</b>	<b>124</b>	<b>0.13</b>
<b>Discrepant Samples</b>	<b>207</b>	<b>0.21</b>
<b>+ Immunoblot</b>	<b>25</b>	
<b>- Immunoblot</b>	<b>182</b>	

# Serology Italy – 3 Tier Lab Testing

	Number	%
<b>Samples</b>	<b>96,468</b>	
+ ELISA	331	0.36
+ E & AGID	124	0.13
<b>Discrepant Samples</b>	<b>207</b>	<b>0.21</b>
+ Immunoblot	25	
- Immunoblot	182	
<b>False + ELISA</b>	<b>182/96,468</b>	<b>0.19</b>
<b>False – AGID</b>	<b>25/96,468</b>	<b>0.026</b>

# Serologic Responses to EIA V – Field Samples




## False+ ELISAs

Animal	Virus <sup>2</sup>	AGID	ELISAs Tests		Immunoblot		
			USkits <sup>3</sup>	IT <sup>4</sup>	p26	gp45	gp90
Judged False Positive							
BG Filly 11/94	ND	?	-/-/+	<1:6			
BG filly 1/95	ND	NEG	-/-/+	<1:6			

React with <2 major proteins of EIA V

# Serologic Responses to EIAV – Field Samples

## False+ ELISAs






Animal	Virus <sup>2</sup>	AGID	ELISAs Tests		Immunoblot		
			USkits <sup>3</sup>	IT <sup>4</sup>	p26	gp45	gp90
<b>Judged False Positive</b>							
BG Filly 11/94	ND	?	-/-/+	<1:6			
BG filly 1/95	ND	NEG	-/-/+	<1:6			
Sugar	ND	NEG	+/-/+	1:96			

React with <2 major proteins of EIAV

Reactions such as Sugar are **extremely rare!**

Requires immunoblot for confirmation

# Serologic Responses to EIAV – Field Samples

Animal	Virus <sup>2</sup>	AGID	ELISAs Tests		Immunoblot		
			USkits <sup>3</sup>	IT <sup>4</sup>	p26	gp45	gp90
Field samples							
Judged True Positive							
Jethro 7/02	ND	NEG	+ / + / -	<1:6			
Jethro 3/11	ND	NEG	+ / + / -	<1:6			
Shadow 8/02	ND	NEG	+ / + / + <sup>6</sup>	<1:6			
Reference Positive Serums							
Flicker W+	Yes	NEG	+ / + / +	1:8			
USDA W+	???	1	+ / + / +	1:48			

# Three Tier Strategy: Field Testing Italy

First tier

ELISA

Second

E+ AGID

Third

E+A+Blot

Is there a need to adopt it more widely?

**Yes, 17% (25/149) of equids AB+ for EIA  
missed by routine AGID in this survey**

**Vet Record (in press)**

# Three Tier Strategy: Field Testing

## Comments-Perspective:

- 1 -Official recognition of limitations of AGID
- 2 -Field proficiency test: on routine performance
- 3 -EU 1<sup>st</sup> Lab proficiency test results surprising  
Better test of accuracy than USDA  
“If too many do not pass it was a bad test”
- 4 -Use investment by the industry wisely  
In US, >US\$70,000,000/yr

# **EIA Control: 2012 Indicated changes**

**Test by risk,  
not regulation**

**New lab paradigm:  
3 tier strategy**

